Dabigatran overdose: Case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man

Blood Coagulation and Fibrinolysis

Volumn 26, Issue 2, 2015, Pages 225-229

  Montaruli, Barbara ^a   Erroi, Laura ^a   Vitale, Corrado ^a   Berutti, Silvia ^a   Cosseddu, Domenico ^a   Sivera, Piera ^a   Coglitore, Raimondo ^a   Marangella, Martino ^a   Migliardi, Marco ^a  

^a MAURIZIANO HOSPITAL   (Italy)

Author keywords

activated partial thromboplastin time; dabigatran; diluted thrombin time; ecarin chromogenic assay; hemodialysis; thrombin time

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; DABIGATRAN; ECARIN; FRESH FROZEN PLASMA; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

AGED; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING PARAMETERS; CASE REPORT; CONTINUOUS HEMODIAFILTRATION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG OVERDOSE; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RECTUM HEMORRHAGE; THROMBIN TIME; VERY ELDERLY; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING; DRUG EFFECTS; PROCEDURES; RENAL REPLACEMENT THERAPY;

AGED, 80 AND OVER; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; DRUG OVERDOSE; HUMANS; MALE; RENAL DIALYSIS;

EID: 84922287383     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000221     Document Type: Article

References (11)

1. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis 2013; 61:487-489.
2. Connolly SJ, Ezekowitx MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl Med 2009; 361:1139-1151.
3. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with two doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long Term Anticoagulant Therapy (RELY) Trail. Circulation 2011; 123:2363-2372.
4. Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem 2013; 59:353-362.
5. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2012; 11: 756-760.
6. Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. Br J Haematol 2012; 159:427-429.
7. Tripodi A, Di Iorio G, Lippi G, Testa S, Manotti C. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMe L, SIBio C, and CISMEL. Clin Chem Lab Med 2012; 50:2137-2140.
8. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107:985-997.
9. Hapgood G, Butler J, Malan E, Chunilal S, Tran H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013; 110:308-315.
10. Pernod G, Albaladejo P. pour le GIHP (Group d'intérét en hémostase pé ri-opé ratoire), France. Prise en charge d'un patient traité par dabigatran ou rivaroxaban, au long cours pré sentant une hé morragie ou nécessitant une chirurgie urgente. [Taking charge of patients with long term treatment with Dabigatran or Rivaroxaban with major bleeding or needing urgent/emergency surgery]. Version 2, 20-02-2013. http://www.sisetonline.com/GIHP-NAOemorragia-chirurgia.pdf. (accessed 21 August 2014).
11. Dabigatran (Pradaxa) Laboratory Monitoring Overview. The University of Utah Healthcare; 2011. http://healthcare.utah.edu/thrombosis/newagents (accessed 20 February 2014).